Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/08—Solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/06—Antimigraine agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/08—Antiepileptics; Anticonvulsants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/20—Hypnotics; Sedatives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/22—Anxiolytics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/24—Antidepressants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• This invention relates to liquid pharmaceutical compositions comprising a gamma-aminobutyric acid (GABA) analog and processes for the preparation of the same as well as methods of using such compositions to treat subjects, including human subjects, suffering from certain cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine.
• GABA gamma-aminobutyric acid
• GABA is an inhibitory amino acid found in the mammalian central nervous system (CNS). It has been reported that dysfunctions with GABA neurotransmission in the CNS may contribute or even cause psychiatric and neurological diseases such as epilepsy, schizophrenia, Parkinson's disease, Huntington's Chorea and dyskinesia (Saletu B., et al., International Journal of Clinical Pharmacology, Therapy, and Toxicology, 1986; 24:362-373).
• Gabapentin was found to have anticonvulsant and antispastic activity with extremely low toxicity in man. Gabapentin is presently marketed under the trademark Neurontin® as adjunctive therapy in the treatment of partial seizures in patients with epilepsy.
• U.S. Pat. Nos. 4,024,175 and 4,087,544 disclose the use of gabapentin for the treatment of certain forms of epilepsy, faintness attacks, hypokinesia, and cranial traumas. Additionally, gabapentin brings about an improvement of cerebral functions and thus is useful in treating geriatric patients.
• U.S. Pat. No. 5,084,479 discloses the use of gabapentin in neurodegenerative disorders.
• U.S. Pat. No. 5,025,035 discloses the use of gabapentin in treating depression;
• U.S. Pat. No. 5,510,381 discloses the use of gabapentin in treating mania and bipolar disorders.
• U.S. Pat. No. 6,127,418 discloses the use of gabapentin in treating gastrointestinal damage
• U.S. Pat. Nos. 4,894,476 and 4,960,931 disclose a novel crystalline monohydrate form of gabapentin
• U.S. Pat. Nos. 5,133,451; 5,319,135; 5,362,883; 5,693,845; 5,091,567; and 5,068,413 disclose processes for preparing gabapentin as well as intermediates used in these processes. All of the aforementioned U.S. Patents are incorporated herein by reference.
• GABA analog disclosed in U.S. Pat. No. 5,563,175 for the treatment of seizure disorders including epilepsy, which is herein incorporated by reference.
• U.S. Pat. No. 6,117,906 discloses the use of pregabalin in treating anxiety; U.S. Pat. No. 6,001,876 discloses the use of pregabalin in treating pain; U.S. Pat. No. 6,127,418 discloses the use of pregabalin in treating gastrointestinal damage; and U.S. Pat. Nos. 5,599,973; 5,608,090; 5,684,189; 5,710,304; 5,616,793; 5,629,447; 5,637,767; 5,840,956; 6,046,353; and 6,028,214 disclose processes for preparing pregabalin as well an intermediate used in these processes. All of the aforementioned U.S. Patents are incorporated herein by reference.
• U.S. Pat. No. 4,024,175 discloses the administration of gabapentin enterally or parenterally within wide dosage ranges in liquid and solid form. Subsequently, it was disclosed in U.S. Pat. No. 6,054,482, which is herein incorporated by reference, that gabapentin was converted to a lactam, i.e., 2-azaspiro[4.5]decan-3-one:
• compositions of gabapentin have been limited to solid dosage forms, such as capsules and tablets.
• Pregabalin similar to gabapentin, also is prone to cyclization to a lactam, i.e., 4-isobutyl-pyrrolidin-2-one:
• liquid formulations of gabapentin and pregabalin would be desirable for the treatment of small children and elderly patients, since these patient groups require doses of gabapentin or pregabalin which are easy to swallow and which can be individually dosed.
• the object of the present invention is a liquid pharmaceutical composition which is amenable to high concentrations of a GABA analog, is stable, has low levels of lactam, and has an agreeable taste.
• a GABA analog can be formulated in a stable liquid pharmaceutical composition having low levels of the GABA analog lactam with a pH of about 5.5 to about 7.0 containing at least one polyhydric alcohol. Additionally, the present composition has an agreeable taste.
• a first aspect of the present invention is a liquid pharmaceutical composition of a GABA analog comprising at least one polyhydric alcohol containing 2 to 6 carbon atoms having a pH of about 5.5 to about 7.0.
• a second aspect of the present invention is a method for preparing a liquid pharmaceutical composition of a GABA analog comprising:
• Step (1) adding a polyhydric alcohol containing 2 to 6 carbon atoms to water;
• Step (2) adding a GABA analog to the solution from Step (1);
• Step (3) optionally adjusting the pH of the composition to about 5.5 to about 7.0 to afford the liquid pharmaceutical composition.
• a third aspect of the present invention is a two-component liquid pharmaceutical composition of a GABA analog comprising:
• a first component comprising a powder mixture of a GABA analog and a solid polyhydric alcohol
• a fourth aspect of the present invention is a method for preparing a two-component liquid pharmaceutical composition of a GABA analog comprising:
• Step (1) mixing a GABA analog with a solid polyhydric alcohol to afford a powder mixture
• Step (2) mixing a polyhydric alcohol with a sweetener and a flavor in water to afford a liquid base;
• Step (3) adding the powder mixture to the liquid base to afford the liquid pharmaceutical composition.
• a fifth aspect of the present invention is a liquid pharmaceutical composition of a GABA analog having less than 0.5% by weight of its corresponding lactam.
• a sixth aspect of the present invention is a method of using a liquid pharmaceutical composition of a GABA analog to treat subjects, including human subjects, suffering from cerebral diseases, including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine.
• cerebral diseases including epilepsy, faintness attacks, hypokinesia and cranial traumas, neurodegenerative disorders, depression, mania and bipolar disorders, anxiety, panic, inflammation, renal colic, insomnia, gastrointestinal damage, incontinence, pain, including neuropathic pain, muscular pain, skeletal pain, and migraine.
• polyhydric alcohol refers to an alkyl or aliphatic alcohol containing from 2 to 6 carbon atoms and 2 to 6 hydroxyl groups, such as, for example, glycerol, xylitol, sorbitol, mannitol, and the like.
• GABA analog refers to a compound derived from or based upon the structure of gamma-aminobutyric acid, such as, for example, gabapentin, pregabalin, and the like.
• Other GABA analogs that can be employed in the liquid pharmaceutical compositions of this invention are those referred to in Great Britain provisional patent application 0125807.8, which was filed on Oct. 26, 2001, Great Britain provisional patent application 0109635.3, which was filed on Apr. 19, 2001, and the corresponding PCT patent application that claims priority from the two foregoing provisional applications and which was filed in April of 2002.
• the foregoing applications are incorporated herein by reference in their entirties. Examples of GABA analogs that are referred to in the foregoing references are set forth below.
• R 1 and R 2 are each independently selected from H, straight or branched alkyl of 1-6 carbon atoms, cycloalkyl of from 3-6 carbon atoms, phenyl and benzyl, subject to the proviso that, except in the case of a tricyclooctane compound of formula (XVII), R 1 and R 2 are not simultaneously hydrogen.
• Suitable compounds are:
• liquid pharmaceutical compositions of the present invention comprise a GABA analog, such as, for example, gabapentin, pregabalin, and the like.
• Gabapentin may readily be prepared as described in U.S. Pat. Nos. 5,132,451; 5,319,135; 5,362,883; 5,693,845; 5,091,567; and 5,068,413.
• Pregabalin may readily be prepared as described in U.S. Pat. Nos. 5,563,175; 5,599,973; 5,608,090; 5,684,189; 5,710,304; 5,616,793; 5,629,447; 5,637,767; 5,840,956; 6,046,353; and 6,028,214.
• compositions of the compounds of the present invention are solids and liquids.
• Liquid form preparations include solutions, suspensions and emulsions, for example, water or certain glycol solutions.
• liquid preparations can be formulated in solution in aqueous polyethylene glycol solutions.
• Aqueous solutions suitable for oral use can be prepared by dissolving the active component in water and adding suitable colorants, flavors, and stabilizing and thickening agents as desired.
• Aqueous suspensions suitable for oral use can be made by dispersing the finely divided active component in water with viscous material, such as, natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
• viscous material such as, natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well-known suspending agents.
• solid form preparations which are intended to be converted, shortly before use, to liquid form preparations for oral administration.
• liquid forms include solutions, suspensions, and emulsions.
• These preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.
• liquid pharmaceutical compositions of the present invention it was found that if the formulation is buffered to a pH of about 5.5 to about 7.0 undesired lactam formation can be substantially avoided.
• Preservatives especially suited for oral compositions usually display their optimum antimicrobial activity in the acid range.
• the solubility of the usual preservatives, such as a paraben, sorbic acid, or benzoic acid decreases at low storage temperatures required for the liquid compositions of the present invention. Thus, precipitations and/or insufficient antimicrobial activity due to low concentration of the preservative at these low temperatures is to be expected. Salts of the usual preservatives have better solubility, but as a rule their antimicrobial activity is too weak.
• polyhydric alcohols containing 2 to 6 carbon atoms, preferably 3 to 6 carbon atoms can be used as adjuvants for oral liquid gabapentin and pregabalin compositions.
• glycerol and/or xylitol are used in the liquid compositions of the first aspect of the present invention.
• These adjuvants can be used in high concentration in the desired pH range of about 5.5 to about 7.0. Preferably, between a pH of about 6.0 to about 7.0.
• polyhydric alcohols allow the preparation of acceptably tasting syrups of a GABA analog especially gabapentin or pregabalin which, when cooled to refrigeration temperatures of about 2° to about 10° C., have a storage stability of at least 2 years.
• the polyhydric alcohols may be used in a concentration range of about 25% to about 75% (weight/volume, w/v), preferably about 30% to 75% (w/v) and most preferably about 40% to about 75% (w/v).
• preservatives it is not necessary to add additional preservatives to the liquid compositions of the present invention.
• addition of another preservative may be advantageous (for example, in the case of sterile-filled syrups when the container is used for multiple doses to prevent contamination of the container).
• care must be taken in choosing an additional preservative that can be used in the desired pH range (about 5.5 to about 7.0) that does not interact with the active components and does not accelerate lactam formation.
• benzethonium chloride can be used as an additional preservative.
• flavor improvers can be added to the liquid compositions of the present invention to enhance the taste masking action of the polyhydric alcohols.
• adjuvants which do not contain a reactive aldehyde or keto functionality can be used, since these functionalities react with the active components.
• the flavor improvers must not alter the desired pH range of about 5.5 to about 7.0.
• fruity compositions have proved to be especially effective, such as, for example, aniseed, strawberry and peppermint or aniseed, huckleberry, and peppermint, and the like.
• a storage temperature of about 2° C. to about 10° C., preferably about 2° C. to about 8° C. and more preferably about 4° C. to about 7° C. is required to ensure the stability of the active components and the taste of the liquid composition.
• a liquid pharmaceutical composition of a GABA analog contains less than 0.5% (weight/weight, w/w) of the GABA analog lactam, preferably 0.4% (w/w) of lactam after storage at about 2° C. to about 10° C., preferably about 2° C. to about 8° C. for 18 months to 2 years, preferably 18 months.
• the syrup-like pharmaceutical compositions of the present invention can be filled into single or multiple dose containers.
• single dose containers can be a double sachet of coated aluminum foil which contains two half doses.
• multiple-dose containers are glass or plastic bottles, preferably with childproof closures.
• the multiple dose container is variable in dosage volume and can be provided with an appropriate dosage aid, such as, a measurement beaker, measurement pipette, and the like.
• Another aspect of the present invention is a two-component liquid pharmaceutical composition of a GABA analog such as, for example, gabapentin, pregabalin and the like.
• the composition comprises a first component comprising a powder mixture of a GABA analog and a solid polyhydric alcohol, such as, for example, sorbitol, xylitol, mannitol, and the like, preferably sorbitol, and a second component comprising a liquid syrup base containing a polyhydric alcohol, such as, for example, glycerol and the like, and one or more flavoring agents, such as, for example, artificial menthol flavor, artificial aniseed flavor, artificial blueberry flavor, and sugar and water.
• a GABA analog such as, for example, gabapentin, pregabalin and the like.
• the composition comprises a first component comprising a powder mixture of a GABA analog and a solid polyhydric alcohol, such as, for example, sorbitol, xylit
• the liquid pharmaceutical composition is prepared by dissolving the powder blend into the syrup vehicle at the time the product is dispensed to the patient.
• the liquid composition once prepared should be stored at about 2° C. to about 10° C., preferably about 2° C. to about 8° C., and more preferably about 4° C. to about 7° C. However, the liquid composition may be stored at room temperature for about 2 months without exceeding undesired levels of lactam as previously described.
• Dosages of gabapentin and pregabalin are well-known in the art, and the skilled practitioner will readily be able to determine the dosage amount required for a subject based upon weight and medical history.
• dosages of gabapentin and pregabalin are disclosed in the aforementioned U.S. Patents.
• dosages of gabapentin are disclosed in U.S. Pat. Nos. 4,024,175; 4,087,544; and 6,054,482 and pregabalin in U.S. Pat. No. 5,563,175.
• liquid compositions of pregabalin may be prepared.
• Table 1 contains representative liquid compositions of gabapentin.
• TABLE 1 Liquid Composition of Gabapentin Example 1 a
• Example 2 Example 3
• Example 4 Gabapentin 2.000 5.000 5.000 5.000 Xylitol 20.000 30.000 30.000 29.940
• Hydrochloric acid — 7.720 — 0.1 N Sodium hydroxide, — — 0.770 — 0.1 N Purified water 27.000 16.280 33.230 20.27 pH value 6.2 5.5 7.0 6.5
• Gabapentin or gabapentin monohydrate (U.S. Pat. No. 4,894,476) is blended with sorbitol.
• a sorbitol solution, glycerol, granular sugar, menthol flavor, artificial aniseed flavor, and artificial blueberry flavor are dissolved in distilled water.
• the syrup is prepared by dissolving the powder blend from Step [A] into the syrup base from Step [B].
• the powder blend is stored in aluminum pouches and the syrup base is stored in a glass bottle at room temperature. After preparing the syrup extemporaneously, the syrup is stored under refrigeration.
• Table 2 contains a representative liquid composition of gabapentin.
• TABLE 2 Two-Component Liquid Composition of Gabapentin Powder Blend Gabapentin Monohydrate 9.90 g (Equivalent to 9.00 g gabapentin) Sorbitol 22.50 g Syrup Base Sorbitol Solution 225.00 g Glycerin, USP 180.00 g Sugar, Granular 45.00 g Artificial Menthol Flavor a 56.25 mg Artificial Aniseed Flavor b 22.50 mg Artificial Blueberry Flavor 4.275 g Water, Distilled qs c to 450 mL

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Neurosurgery (AREA)
• Pain & Pain Management (AREA)
• Epidemiology (AREA)
• Psychiatry (AREA)
• Physical Education & Sports Medicine (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Anesthesiology (AREA)
• Urology & Nephrology (AREA)
• Hospice & Palliative Care (AREA)
• Rheumatology (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pyrrole Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Indole Compounds (AREA)

Priority Applications (2)

Applications Claiming Priority (3)

Related Child Applications (1)

Publications (1)

Family

ID=26968180

Family Applications (2)

Family Applications After (1)

Country Status (43)

Cited By (7)

Families Citing this family (26)

Family Cites Families (3)

• 2002
  • 2002-04-29 OA OA1200300296A patent/OA12604A/en unknown
  • 2002-04-29 SI SI200230371T patent/SI1395242T1/xx unknown
  • 2002-04-29 DE DE60213592T patent/DE60213592T2/de not_active Expired - Fee Related
  • 2002-04-29 CZ CZ20033066A patent/CZ299755B6/cs not_active IP Right Cessation
  • 2002-04-29 HU HU0401366A patent/HUP0401366A2/hu unknown
  • 2002-04-29 EA EA200301152A patent/EA008087B1/ru not_active IP Right Cessation
  • 2002-04-29 AP APAP/P/2003/002907A patent/AP1815A/en active
  • 2002-04-29 NZ NZ529173A patent/NZ529173A/en unknown
  • 2002-04-29 BR BR0209973-0A patent/BR0209973A/pt not_active IP Right Cessation
  • 2002-04-29 IL IL15835902A patent/IL158359A0/xx unknown
  • 2002-04-29 HR HR20030833A patent/HRP20030833B1/xx not_active IP Right Cessation
  • 2002-04-29 AU AU2002258026A patent/AU2002258026B2/en not_active Ceased
  • 2002-04-29 GE GE5340A patent/GEP20053620B/en unknown
  • 2002-04-29 SK SK1411-2003A patent/SK286227B6/sk not_active IP Right Cessation
  • 2002-04-29 RS YU87203A patent/RS87203A/sr unknown
  • 2002-04-29 ES ES02727834T patent/ES2265040T3/es not_active Expired - Lifetime
  • 2002-04-29 JP JP2002590939A patent/JP2004534764A/ja active Pending
  • 2002-04-29 KR KR1020037015326A patent/KR100582963B1/ko not_active Expired - Fee Related
  • 2002-04-29 EP EP02727834A patent/EP1395242B1/en not_active Expired - Lifetime
  • 2002-04-29 MX MXPA03009392A patent/MXPA03009392A/es active IP Right Grant
  • 2002-04-29 PL PL02366384A patent/PL366384A1/xx not_active Application Discontinuation
  • 2002-04-29 AT AT02727834T patent/ATE334656T1/de not_active IP Right Cessation
  • 2002-04-29 WO PCT/IB2002/001500 patent/WO2002094220A1/en not_active Ceased
  • 2002-04-29 DK DK02727834T patent/DK1395242T3/da active
  • 2002-04-29 CA CA002446574A patent/CA2446574C/en not_active Expired - Fee Related
  • 2002-04-29 PT PT02727834T patent/PT1395242E/pt unknown
  • 2002-04-29 CN CNB028098080A patent/CN100346779C/zh not_active Expired - Fee Related
  • 2002-04-29 EE EEP200300587A patent/EE200300587A/xx unknown
  • 2002-05-21 MY MYPI20021869A patent/MY128615A/en unknown
  • 2002-05-22 EG EG20020541A patent/EG24078A/xx active
  • 2002-05-23 PE PE2002000433A patent/PE20030087A1/es not_active Application Discontinuation
  • 2002-05-23 DO DO2002000403A patent/DOP2002000403A/es unknown
  • 2002-05-23 AR ARP020101922A patent/AR033922A1/es unknown
  • 2002-05-24 PA PA20028545901A patent/PA8545901A1/es unknown
  • 2002-05-24 SV SV2002001053A patent/SV2003001053A/es not_active Application Discontinuation
  • 2002-05-28 US US10/156,213 patent/US20020198261A1/en not_active Abandoned
• 2003
  • 2003-06-24 US US10/602,215 patent/US7256216B2/en not_active Expired - Lifetime
  • 2003-10-09 IS IS6986A patent/IS2428B/is unknown
  • 2003-10-28 ZA ZA2003/08393A patent/ZA200308393B/en unknown
  • 2003-11-17 CR CR7150A patent/CR7150A/es not_active Application Discontinuation
  • 2003-11-19 MA MA27406A patent/MA27026A1/fr unknown
  • 2003-11-21 BG BG108376A patent/BG108376A/bg unknown
  • 2003-11-24 NO NO20035200A patent/NO20035200D0/no not_active Application Discontinuation
• 2006
  • 2006-08-10 CY CY20061101125T patent/CY1105147T1/el unknown

Also Published As

Similar Documents

Legal Events